-9.76%
Today
Loading 1D prices…
Company profile
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
NYSE
Display currency
USD
Location
Bedminster, NJ, United States
Employees
2
Fiscal year end
1231
CIK
1582554
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| GNPXGenprex Inc. Common Stock | $2.7M | $0.00 | — | -$382.80 | 0.00% | Unrated |
| PPBTPurple Biotech Ltd. American Depositary Shares | $2.8M | $0.00 | — | -$54.00 | -1.15% | Buy |
| SPRCSciSparc Ltd. Ordinary Shares | $3M | $856K | -1422.78% | $203.89 | +2.63% | Unrated |
| ARTLArtelo Biosciences Inc. Common Stock | $3M | $0.00 | — | -$37.75 | -3.55% | Hold |
| PRFXPRF Technologies Ltd. Ordinary Shares | $3M | $17K | -29541.18% | -$7.47 | -7.33% | Unrated |